News

Primary endpoint met in phase II/III clinical study of investigational Parkinson’s disease treatment safinamide in Japan

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, CEO: Daikichiro Kobayashi, “Meiji”) announced today that

Newron Provides End of Year Corporate Update

Significant progress in 2017 including US Xadago approval, STARS initiation, Evenamide results Milan, Italy – December 11, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX:

Newron to Participate in Upcoming Investor Conferences in November and December

Milan, Italy - November 14, 2017 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients

Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Congress Findings

- Advisory Board Characterizes Illness and Treatment Patterns - Rett Congress Reviews Multi-Organ Impact of Single Symptoms Milan, Italy & Morristown, N.J. – November 7, 2017

Newron Pharmaceuticals to Present at European Rett Syndrome Congress and Host Advisory Board Meeting

- Continued advancement of the International Burden of Disease in Rett Syndrome Study - Oral presentation on findings from concept elicitation interviews with caregivers and

Newron Pharmaceuticals Supports Rett Syndrome Awareness Month this October

Milan, Italy & Morristown, N.J. – October 6, 2017 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel

Newron raises CHF 27.0 Million in a private placement of new shares

 Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia THIS IS A RESTRICTED COMMUNICATION AND YOU

Newron raises CHF 27.0 Million in a private placement of new shares.

Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia THIS IS A RESTRICTED COMMUNICATION AND YOU MUST

Newron launches a private placement of new shares.

Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia THIS IS A RESTRICTED COMMUNICATION AND YOU MUST

Newron launches a private placement of new shares

Not for release, publication or distribution, directly or indirectly, in the United States of America, Canada, Japan or Australia THIS IS A RESTRICTED COMMUNICATION AND YOU MUST